The mTOR inhibitor rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cells.

Patients with ER/HER2-positive breast cancer have a poor prognosis and are less responsive to selective estrogen receptor modulators; this is presumably due to the crosstalk between ER and HER2. Fatty acid synthase (FASN) is essential for the survival and maintenance of the malignant phenotype of br...

Full description

Bibliographic Details

Published in:	PLoS ONE
Main Authors:	Chen Yan, Huang Wei, Zheng Minjuan, Xue Yan, Yang Jingyue, Liu Wenchao, Han Sheng
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Online Access:	http://europepmc.org/articles/PMC4035285?pdf=render